Substance, use in relation to COVID-19: A scoping review.
Substance, use in relation to COVID-19: A scoping review.
复制标题
物质，与COVID-19的使用：范围审查。
DOI：
10.1016/j.addbeh.2021.107213
复制
发表时间：
2022-04
影响因子：
4.4
通讯作者：
Khoshnood K
中科院分区：
文献类型：
--
作者：
Kumar N;Janmohamed K;Nyhan K;Martins SS;Cerda M;Hasin D;Scott J;Sarpong Frimpong A;Pates R;Ghandour LA;Wazaify M;Khoshnood K
我们针对疫情期间各种形式的物质使用进行了范围审查，研究物质使用对COVID-19感染、严重程度和疫苗接种的影响，以及COVID-19对物质使用治疗和比率的影响。于2020年9月15日及2021年4月15日进行了一次范围审查，汇集了同行评审和灰色文献，重点关注物质使用和COVID-19，以收集任何新的研究。检索了3个文献数据库（Web of Science Core Collection、Embase、PubMed）和几个预印本服务器（EuropePMC、bioRxiv、medRxiv、F1000、PeerJ Preprints、PsyArXiv、Research Square）。我们只包括英语原创研究。在摘要和标题筛选阶段筛选的1564篇文章中，我们纳入了111项符合纳入标准的研究（同行评审：98项，灰色文献：13项）。除了涉及烟草或酒精的药物使用外，对其他药物使用的研究有限。我们注意到，从事物质使用的个人患COVID-19严重程度的风险增加，患有COVID-19并从事物质使用的美国黑人的结果比白色美国人更糟糕。在大流行病早期，提供治疗方面存在问题，但随着大流行病的发展，远程保健的使用有所增加。COVID-19焦虑与物质使用增加有关。我们对COVID-19期间迄今为止的研究进行了范围审查，发现了显著的研究差距，即需要对疫苗、COVID-19担忧（如焦虑和担忧）、低收入至中等收入国家（LMIC）以及药物使用中研究不足的主题进行研究，并在适当情况下探索使用定性技术和干预措施。我们还注意到，临床医生可以筛查和治疗表现出物质使用的个人，以减轻大流行的影响。这项研究由耶鲁大学社会和政策研究所和霍洛维茨社会政策基金会资助。卫生署由NIDA赠款（R 01 DA 048860）资助。资助机构在研究数据的设计、分析或解释方面没有任何作用。
We conducted a scoping review focused on various forms of substance use amid the pandemic, looking at both the impact of substance use on COVID-19 infection, severity, and vaccine uptake, as well as the impact that COVID-19 has had on substance use treatment and rates. A scoping review, compiling both peer-reviewed and grey literature, focusing on substance use and COVID-19 was conducted on September 15, 2020 and again in April 15, 2021 to capture any new studies. Three bibliographic databases (Web of Science Core Collection, Embase, PubMed) and several preprint servers (EuropePMC, bioRxiv, medRxiv, F1000, PeerJ Preprints, PsyArXiv, Research Square) were searched. We included English language original studies only. Of 1564 articles screened in the abstract and title screening phase, we included 111 research studies (peer-reviewed: 98, grey literature: 13) that met inclusion criteria. There was limited research on substance use other than those involving tobacco or alcohol. We noted that individuals engaging in substance use had increased risk for COVID-19 severity, and Black Americans with COVID-19 and who engaged in substance use had worse outcomes than white Americans. There were issues with treatment provision earlier in the pandemic, but increased use of telehealth as the pandemic progressed. COVID-19 anxiety was associated with increased substance use. Our scoping review of studies to date during COVID-19 uncovered notable research gaps namely the need for research efforts on vaccines, COVID-19 concerns such as anxiety and worry, and low- to middle-income countries (LMICs) and under-researched topics within substance use, and to explore the use of qualitative techniques and interventions where appropriate. We also noted that clinicians can screen and treat individuals exhibiting substance use to mitigate effects of the pandemic. Study was funded by the Institution for Social and Policy Studies, Yale University and The Horowitz Foundation for Social Policy. DH was funded by a NIDA grant (R01DA048860). The funding body had no role in the design, analysis, or interpretation of the data in the study.
登录
查看更多内容
DOI：
10.1111/acer.14555
发表时间：
2021-03-05
期刊：
ALCOHOL-CLINICAL AND EXPERIMENTAL RESEARCH
影响因子：
--
作者：
Barrio, Pablo;Baldaqui, Nuria;Manthey, Jakob
通讯作者：
Manthey, Jakob
DOI：
10.3390/ijerph17176287
发表时间：
2020-08-28
影响因子：
--
作者：
Cancello R;Soranna D;Zambra G;Zambon A;Invitti C
通讯作者：
Invitti C
影响因子：
5.5
作者：
Bandara, Sachini;Kennedy-Hendricks, Alene;Saloner, Brendan
通讯作者：
Saloner, Brendan
影响因子：
2
作者：
Caponnetto, Pasquale;Inguscio, Lucio;Polosa, Riccardo
通讯作者：
Polosa, Riccardo
影响因子：
3.7
作者：
Brondani MA;Alan R;Donnelly L
通讯作者：
Donnelly L